Dyadic International, Inc. (DYAI) is a publicly traded Healthcare sector company. As of May 21, 2026, DYAI trades at $0.74 with a market cap of $26.24M and a P/E ratio of -3.20. DYAI moved +1.50% today. Year to date, DYAI is -18.95%; over the trailing twelve months it is -30.42%. Its 52-week range spans $0.65 to $2.20. Analyst consensus is buy with an average price target of $0.00. Rallies surfaces DYAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Dyadic International Posts Q1 Revenue Surge, Unveils New Biomanufacturing Partnerships: Dyadic International’s Q1 2026 earnings call highlighted a year-over-year revenue surge and outlined plans to expand its C1 enzyme production platform. Management also announced new strategic partnerships aimed at accelerating biomanufacturing scale-up in the second half of 2026.
| Metric | Value |
|---|---|
| Price | $0.74 |
| Market Cap | $26.24M |
| P/E Ratio | -3.20 |
| EPS | $-0.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.20 |
| 52-Week Low | $0.65 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.09M |
| Net Income | $-7.36M |
| Gross Margin | 24.93% |
1 analysts cover DYAI: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $0.00.